A perspective on intermittent fasting and cardiovascular risk in the era of obesity pharmacotherapy by Aristides G. Eliopoulos, Aristides G. Eliopoulos, Aristides G. Eliopoulos, Kalliopi K. Gkouskou, Kalliopi K. Gkouskou, Konstantinos Tsioufis, Despina Sanoudou, Despina Sanoudou, Despina Sanoudou

Get full text

Responsible governance of genomics data and biospecimens in the context of broad consent: experiences of a pioneering access committee in Africa by Kobus Herbst, R Kerr, Daima Bukini, Ahmed Rebai, Akin Abayomi, P Andanda, J Mabuka, R Wamuyu, C Dandara

Get full text

Effect of physiochemical parameters on yield and biological efficiency of Volvariella volvacea cultivated on empty fruit bunch pellets by Nur Fariha Amir, Aslizah Mohd-Aris, Tuan Norhafizah Tuan-Zakaria, Noor Azrimi Umor, Azhar Mohamad, Nornadiah Mohd Razali, Farida Zuraina Mohd Yusof, Sumaiyah Abdullah

Get full text

Efficacy and safety of rivaroxaban in preventing venous thromboembolism in postoperative patients with gynecological malignancies: protocol for a randomised controlled open-label t... by Hong Zhou, Fei He, Ting Wei, Shuyi Wu, Jinhua Zhang, Huan Yi

“…Secondary endpoints will be any bleeding event, medication compliance rate, rivaroxaban pharmacokinetics and pharmacogenomics. The sample size required for the G-alfalfa trial is derived based on power calculations of the VTE incidence in the two intervention regimens in previous literature.Ethics and dissemination This study was approved by the Ethics Committee of Fujian Maternal and Child Health Hospital on 2 April 2024 (Approval No.:2023KY174-03). …”
Get full text

Therapeutic potential of brentuximab vedotin in breast cancer and lymphoma via targeted apoptosis and gene regulation by Abeer Ezzat, Mohga Shafiek, Shimaa Shawki, Shaimaa Abdel-Ghany, Mahmoud Nazih, Hussein Sabit

Get full text

Involvement of HLADQA1*05 in Patients with Inflammatory Bowel Disease Treated with Anti-TNF Drugs by Anna Pau, Ilaria Galliano, Elisa Barnini, Maddalena Dini, Antonio Pizzol, Alice Ponte, Stefano Gambarino, Pier Luigi Calvo, Massimiliano Bergallo

“…However, immunogenicity—where anti-drug antibodies diminish effectiveness—remains an issue, often requiring dose changes or combination therapies. Pharmacogenomics is increasingly applied in IBD to personalise treatment, especially since genetic factors like the HLA-DQA1*05 variant heighten the immunogenicity risk with IFX. …”
Get full text

Transcriptomic and functional characterization of megakaryocytic-derived platelet-like particles: impaired aggregation and prominent anti-tumor effects by Kaitlin Garofano, Vera Mariani, Kameron Rashid, Sumanun Suwunnakorn, Alfateh Sidahmed, Anelia Horvath, Sanjay B. Maggirwar, Travis J. O’Brien, Minoli A. Perera, Michael Whalen, Norman H. Lee

Get full text

Tacrolimus- and Mycophenolate-Mediated Toxicity: Clinical Considerations and Options in Management of Post-Transplant Patients by Alan D. Kaye, Shivam S. Shah, Coplen D. Johnson, Adalyn S. De Witt, Austin S. Thomassen, Charles P. Daniel, Shahab Ahmadzadeh, Sridhar Tirumala, Kristin Nicole Bembenick, Adam M. Kaye, Sahar Shekoohi

“…Therapeutic drug monitoring (TDM) and pharmacogenomics have emerged as essential strategies for mitigating these toxicities. …”
Get full text

Comparison of global transcriptomes for nontyphoidal Salmonella clinical isolates from pediatric patients with and without bacteremia after their interaction with human intestinal... by Buyandelger Batsaikhan, Pei-Chun Lin, Katsumi Shigemura, Yu-Wei Wu, Reo Onishi, Pei-Ru Chang, Hung-Yen Cheng, Shiuh-Bin Fang

Get full text

The PRC2.1 subcomplex opposes G1 progression through regulation of CCND1 and CCND2 by Adam D Longhurst, Kyle Wang, Harsha Garadi Suresh, Mythili Ketavarapu, Henry N Ward, Ian R Jones, Vivek Narayan, Frances V Hundley, Arshia Zernab Hassan, Charles Boone, Chad L Myers, Yin Shen, Vijay Ramani, Brenda J Andrews, David P Toczyski

Get full text

Lipids as key biomarkers in unravelling the pathophysiology of obesity-related metabolic dysregulation by Anis Adibah Osman, Siok-Fong Chin, Lay-Kek Teh, Noraidatulakma Abdullah, Nor Azian Abdul Murad, Rahman Jamal

Get full text

Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study by Alizée Bozonnat, Marie Beylot-Barry, Olivier Dereure, Michel D’Incan, Gaëlle Quereux, Emmanuella Guenova, Marie Perier-Muzet, Stephane Dalle, Florent Grange, Manuelle-Anne Viguier, Caroline Ram-Wolff, Laurence Feldmeyer, Helmut Beltraminelli, Nathalie Bonnet, Florent Amatore, Eve Maubec, Nathalie Franck, Laurent Machet, François Chasset, Florence Brunet-Possenti, Jean-David Bouaziz, Maxime Battistella, Marie Donzel, Anne Pham-Ledard, Claudia Bejar, Hélène Moins-Teisserenc, Samia Mourah, Philippe Saiag, Ewa Hainaut, Catherine Michel, Guido Bens, Henri Adamski, François Aubin, Serge Boulinguez, Pascal Joly, Billal Tedbirt, Isabelle Templier, Laura Troin, Henri Montaudié, Saskia Ingen-Housz-Oro, Sarah Faiz, Laurent Mortier, Gabor Dobos, Martine Bagot, Matthieu Resche-Rigon, Claire Montlahuc, Arnaud Serret-Larmande, Adèle de Masson

Get full text

Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: iPHAR... by Xandra García-González, Alberto M Borobia, Antonio J Carcas, Miriam Estébanez, Montserrat Carmona, Irene García García, Francisco Abad-Santos, Luis A López-Fernández, Esther Cubo, Iñaki Imaz-Iglesia, Alicia Marín-Candón, Miriam Saiz-Rodríguez, Irene Taladriz-Sender, Pedro Arias, Rocío Rosas-Alonso, Enrique Seco-Meseguer, Stefan Stewart, Elena Diago-Sempere, María del Mar García Saiz, Emilio J Laserna-Mendieta, Ana M Peiró, Magí Farré, Consuelo Rodriguez-Jimenez, Judith Sanabria-Cabrera, Lucia Pedrosa, Ignacio Bernardino, Javier Guiijarro-Eguinoa, Arturo Gómez López De Las Huertas, Susana Martín-López, Olga Hladun Alvaro, Vicente Arrate, Ana Fries, Daniel Rodriguez Díaz, Fernando Marqués García, Núria Alonso Pedrol, Modesto M Maestre Muñiz, Leticia Rodríguez Alcolado, Carlos Ortiz-Bautista, Angela Remesal-Doblado, María Isabel Lucena, Zaida Salmón González, Inmaculada Coca-Prieto

Get full text

The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force by Hélène Verdoux, Robert A. Bittner, Alkomiet Hasan, Mishal Qubad, Elias Wagner, Alexis Lepetit, Manuel Arrojo-Romero, Christian Bachmann, Marieke Beex-Oosterhuis, Jan Bogers, Andreja Celofiga, Dan Cohen, Domenico de Berardis, Marc de Hert, Carlos de Las Cuevas, Bjørn H. Ebdrup, Konstantinos N. Fountoulakis, Daniel Guinart, Dolores Keating, Miloslav Kopeček, John Lally, Judit Lazáry, Jurjen J. Luykx, Olalla Maronas Amigo, Espen Molden, Jimmi Nielsen, Brian O’Donoghue, Pierre Oswald, Flavian S. Radulescu, Christopher Rohde, Marina Sagud, Emilio J. Sanz, Ivona Šimunović Filipčić, Iris E. Sommer, Heidi Taipale, Jari Tiihonen, Heli Tuppurainen, Selene Veerman, Alina Wilkowska, Edoardo Spina, Peter Schulte

Get full text

Association of Single Nucleotide Polymorphisms in the IL-18 Gene with Production of IL-18 Protein by Mononuclear Cells from Healthy Donors by Khripko Olga Pavlovna, Sennikova Nadegda Sergeevna, Lopatnikova Julia Anatolievna, Khripko Jurii Ivanovich, Filipenko Maxim Leonidovich, Khrapov Evgenii Alexandrovich, Gelfgat Evgenii L'vovich, Yakushenko Elena Vladimirovna, Kozlov Vladimir Alexandrovich, Sennikov Sergei Vitalievich

Get full text

Biomarker-Based Targeting of the Androgen-Androgen Receptor Axis in Advanced Prostate Cancer by Manish Kohli, Rui Qin, Rafael Jimenez, Scott M. Dehm

“…Specific examples of rational clinical trial designs incorporating potential predictive biomarkers from these pathways will illustrate several aspects of pharmacogenetic and pharmacogenomic predictive biomarker development in advanced prostate cancer therapeutics.…”
Get full text

Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon? by Adriana Dana Oprea, Wanda M. Popescu

“…Variable response to clopidogrel has received close attention, and pharmacokinetic, pharmacodynamic, and pharmacogenomic factors have been identified as culprits. …”
Get full text

An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity by Chun-Bing Chen, Riichiro Abe, Ren-You Pan, Chuang-Wei Wang, Shuen-Iu Hung, Yi-Giien Tsai, Wen-Hung Chung

“…., maculopapular exanthema and urticaria) to severe systemic reactions, such as anaphylaxis, drug reactions with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS), or Stevens–Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). Current pharmacogenomic studies have made important strides in the prevention of some drug hypersensitivity through the identification of relevant genetic variants, particularly for genes encoding drug-metabolizing enzymes and human leukocyte antigens (HLAs). …”
Get full text

Linezolid and serotonin syndrome by Haytham A. Wali

“…Developing comprehensive clinical guidelines and education programs for healthcare providers is crucial to improve linezolid’s safety profile. Exploring pharmacogenomic approaches and alternative therapies with lower serotonin syndrome risks is recommended to enhance patient outcomes while maintaining linezolid’s efficacy in treating severe bacterial infections.…”
Get full text

Actively protective combinatorial analysis: A scalable novel method for detecting variants that contribute to reduced disease prevalence in high-risk individuals by J Sardell, S Das, K Taylor, C Stubberfield, A Malinowski, M Strivens, S Gardner

“…These protective signatures can potentially be used to identify novel drug targets, pharmacogenomic and/or therapeutic mRNA opportunities and to better stratify patients by overall disease risk and mechanistic subtype.We describe the method and illustrate how it offers increased power for detecting disease-associated genetic variants relative to traditional methods. …”
Get full text